search
Back to results

the Prophylaxis of Recurrent Pouchitis After Fecal Microbiota Transplant in UC With Ileo-anal Anastomosis (POCA)

Primary Purpose

Pouchitis

Status
Recruiting
Phase
Phase 3
Locations
France
Study Type
Interventional
Intervention
fecal microbiota
Placebo
Sponsored by
Nantes University Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Pouchitis focused on measuring recurrent pouchitis, fecal microbiota transplant

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

4.2. INCLUSION CRITERIA

Subjects must satisfy the following criteria to be enrolled in the study:

  1. Male or female ≥ 18 years at the time of signing the informed consent form (ICF).
  2. Subject must understand and voluntarily sign an ICF prior to conduct the study related assessments/procedure.
  3. Willing and able to adhere to the study visit scheduled and other protocol requirements.
  4. Subjects must have been operated with ileal pouch anal anastomosis (IPAA) with a duration of at least 6 month prior the screening visit.
  5. Subject must have a diagnosis of recurrent pouchitis defined as at least 2 episodes in the last year or relapsing immediately after a reasonable response to antibiotherapy (the antifungal medication is allowed until the day before transplantation).
  6. Subject must be in remission with a Pouchitis Disease Activity Index (PDAI) < 7 at the screening
  7. Subject must affiliation with social security system or beneficiary from such system
  8. Female of childbearing potential must have a negative pregnancy test at screening and must agree to practice effective methods of contraception

4.3. NON-INCLUSION CRITERIA

Subjects who meet any of the following non inclusion criteria could not be enrolled in this study:

  1. Crohn disease or indeterminate colitis
  2. Anastomotic stenosis
  3. Subject with prior treatment by probiotic within 3 month prior to the transplantation visit
  4. Subject with prior treatment by corticosteroids within 6 weeks prior to the transplantation visit
  5. Subject with prior treatment by immunosuppressors within 3 month prior to the transplantation visit
  6. Prior treatment with a biologic within 3 month prior the transplantation visit
  7. Documented active infection of any kind in the last 6 months likely to require anti-infective treatment during the next months
  8. Absolute neutrophil count (ANC) < 1.5 x 109 /L (1,500 mm3)
  9. Infection with chronic HIV
  10. Pregnant female or breastfeeding
  11. Chronic medical or psychiatric disease that may interfere with subject's ability to comply with study procedures
  12. Administration of investigational drug within 3 months prior to planned FMT
  13. Adults under guardianship, Safeguard justice or trusteeship
  14. Subject with difficulty in follow-up (vacation, job transfer, geographical distance, lack of motivation).
  15. Patients with contraindication to colonoscopy or anesthesia (if necessary)

Sites / Locations

  • CHU Angers
  • CHU EstaingRecruiting
  • Hopital Beaujon, ClichyRecruiting
  • CHU Henry MondorRecruiting
  • CHU Claude HuriezRecruiting
  • CHU Lyon SudRecruiting
  • CHU of NantesRecruiting
  • CHU de l'Archet 2Recruiting
  • Hopital Saint AntoineRecruiting
  • Groupe Hospitalier Sud- Hopital Haut-lévêqueRecruiting
  • CHU PontchaillouRecruiting
  • CHU ToulouseRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

fecal microbiota

placebo

Arm Description

Outcomes

Primary Outcome Measures

Number of days between the date of transplantation and the date of relapse according to physiological and endoscopic parameter (pochitis disease activity index)

Secondary Outcome Measures

Number of relapse rate according to physiological and endoscopic parameter (pochitis disease activity index)
Number of relapse rate according to pochitis disease activity index (physiological and endoscopic parameter)
Number of days within the transplantation and the instauration of an antibiotherapy or alternative treatment
Number of adverse events
Number of fecal microbiota engraftment by 16S sequencing
Number of evolution of health-related to disability according to physiological and endoscopic parameter (pochitis disease activity index)
Number of evolution of health-related to disability according to physiological and endoscopic parameter (pochitis disease activity index)
Number of evolution of health-related to disability according to physiological and endoscopic parameter (pochitis disease activity index)
Number of evolution of health-related to disability according to physiological and endoscopic parameter (pochitis disease activity index)
Number of evolution of health-related to disability according to physiological and endoscopic parameter (pochitis disease activity index)

Full Information

First Posted
May 2, 2018
Last Updated
June 14, 2023
Sponsor
Nantes University Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT03524352
Brief Title
the Prophylaxis of Recurrent Pouchitis After Fecal Microbiota Transplant in UC With Ileo-anal Anastomosis
Acronym
POCA
Official Title
Prospective Multicenter Randomized Controlled Double-blind Label Study of the Prophylaxis of Recurrent Pouchitis After Fecal Microbiota Transplant in UC With Ileo-anal Anastomosis
Study Type
Interventional

2. Study Status

Record Verification Date
June 2023
Overall Recruitment Status
Recruiting
Study Start Date
March 12, 2020 (Actual)
Primary Completion Date
May 12, 2028 (Anticipated)
Study Completion Date
May 12, 2028 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Nantes University Hospital

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
Ulcerative colitis (UC) is a chronic inflammatory digestive (IBD) disease medically treated with corticosteroids, aminosalicylates, immunomodulators, and biologics. Almost one third of UC patients will require surgical interventions because of fulminant colitis, dysplasia, cancer, or medical refractory diseases. Restorative proctocolectomy with ileal pouch-anal anastomosis (IPAA) is the current standard surgical intervention. Anastomotic leak, pouch failure, pelvic sepsis, and pouch ischemia can occur after the procedure, but the most common long-term complication is pouchitis, an idiopathic inflammatory condition involving the ileal reservoir. Symptoms of pouchitis are increased stool frequency, urgency, incontinence, bloody stools, abdominal or pelvic discomfort, fatigue, malaise, and fever. The prevalence of pouchitis ranges from 23 to 46 %, with an annual incidence up to 40 %. Though the majority of initial cases of pouchitis are easily managed with a short course of antibiotics, in about 5 to 15 % of cases, inflammation of the pouch becomes chronic with very few treatments available. Fecal microbiota transplantation (FMT) is a novel therapy to transfer normal intestinal flora from a healthy donor to a patient with a medical condition potentially caused by disrupted homeostasis of intestinal microbiota or dysbiosis. FMT has been widely used in refractory Clostridium difficile infection (CDI) and recently it has gained popularity for treatment of inflammatory bowel disease (IBD). Previous studies suggested that manipulating the composition of intestinal flora through antibiotics, probiotics, and prebiotic achieved significant results for treating acute episodes of UC-associated pouchitis. However, currently there is no established effective treatment for chronic antibiotic dependent pouchitis. Our project aims to evaluate the delay of relapse in chronic recurrent pouchitis after FMT versus sham transplantation.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pouchitis
Keywords
recurrent pouchitis, fecal microbiota transplant

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
42 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
fecal microbiota
Arm Type
Experimental
Arm Title
placebo
Arm Type
Placebo Comparator
Intervention Type
Other
Intervention Name(s)
fecal microbiota
Intervention Description
fecal microbiota in suspension
Intervention Type
Other
Intervention Name(s)
Placebo
Intervention Description
sterile saline
Primary Outcome Measure Information:
Title
Number of days between the date of transplantation and the date of relapse according to physiological and endoscopic parameter (pochitis disease activity index)
Time Frame
106 weeks
Secondary Outcome Measure Information:
Title
Number of relapse rate according to physiological and endoscopic parameter (pochitis disease activity index)
Time Frame
24 weeks
Title
Number of relapse rate according to pochitis disease activity index (physiological and endoscopic parameter)
Time Frame
52 weeks
Title
Number of days within the transplantation and the instauration of an antibiotherapy or alternative treatment
Time Frame
52 weeks
Title
Number of adverse events
Time Frame
104 weeks
Title
Number of fecal microbiota engraftment by 16S sequencing
Time Frame
8 weeks
Title
Number of evolution of health-related to disability according to physiological and endoscopic parameter (pochitis disease activity index)
Time Frame
weeks -5
Title
Number of evolution of health-related to disability according to physiological and endoscopic parameter (pochitis disease activity index)
Time Frame
0 week
Title
Number of evolution of health-related to disability according to physiological and endoscopic parameter (pochitis disease activity index)
Time Frame
8 weeks
Title
Number of evolution of health-related to disability according to physiological and endoscopic parameter (pochitis disease activity index)
Time Frame
24 weeks
Title
Number of evolution of health-related to disability according to physiological and endoscopic parameter (pochitis disease activity index)
Time Frame
52 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
4.2. INCLUSION CRITERIA Subjects must satisfy the following criteria to be enrolled in the study: Male or female ≥ 18 years at the time of signing the informed consent form (ICF). Subject must understand and voluntarily sign an ICF prior to conduct the study related assessments/procedure. Willing and able to adhere to the study visit scheduled and other protocol requirements. Subjects must have been operated with ileal pouch anal anastomosis (IPAA) with a duration of at least 6 month prior the screening visit. Subject must have a diagnosis of recurrent pouchitis defined as at least 2 episodes in the last year or relapsing immediately after a reasonable response to antibiotherapy (the antifungal medication is allowed until the day before transplantation). Subject must be in remission with a Pouchitis Disease Activity Index (PDAI) < 7 at the screening Subject must affiliation with social security system or beneficiary from such system Female of childbearing potential must have a negative pregnancy test at screening and must agree to practice effective methods of contraception 4.3. NON-INCLUSION CRITERIA Subjects who meet any of the following non inclusion criteria could not be enrolled in this study: Crohn disease or indeterminate colitis Anastomotic stenosis Subject with prior treatment by probiotic within 3 month prior to the transplantation visit Subject with prior treatment by corticosteroids within 6 weeks prior to the transplantation visit Subject with prior treatment by immunosuppressors within 3 month prior to the transplantation visit Prior treatment with a biologic within 3 month prior the transplantation visit Documented active infection of any kind in the last 6 months likely to require anti-infective treatment during the next months Absolute neutrophil count (ANC) < 1.5 x 109 /L (1,500 mm3) Infection with chronic HIV Pregnant female or breastfeeding Chronic medical or psychiatric disease that may interfere with subject's ability to comply with study procedures Administration of investigational drug within 3 months prior to planned FMT Adults under guardianship, Safeguard justice or trusteeship Subject with difficulty in follow-up (vacation, job transfer, geographical distance, lack of motivation). Patients with contraindication to colonoscopy or anesthesia (if necessary)
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Trang POISSON
Phone
+33 2 40 08 75 59
Email
caroline.trang@chu-nantes.fr
Facility Information:
Facility Name
CHU Angers
City
Angers
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
DIB
Facility Name
CHU Estaing
City
Clermont-Ferrand
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
BUISSON
Facility Name
Hopital Beaujon, Clichy
City
Clichy
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
BOUHNIK
Facility Name
CHU Henry Mondor
City
Créteil
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
UZZAN
Facility Name
CHU Claude Huriez
City
Lille
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
NACHURY
Facility Name
CHU Lyon Sud
City
Lyon
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
NANCEY
Facility Name
CHU of Nantes
City
Nantes
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Trang
Email
caroline.trang@chu-nantes.fr
Facility Name
CHU de l'Archet 2
City
Nice
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
HEBUTERNE
Facility Name
Hopital Saint Antoine
City
Paris
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sokol
Facility Name
Groupe Hospitalier Sud- Hopital Haut-lévêque
City
Pessac
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
LAHARIE
Facility Name
CHU Pontchaillou
City
Rennes
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
BOUGUEN
Facility Name
CHU Toulouse
City
Toulouse
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
ALRIC

12. IPD Sharing Statement

Citations:
PubMed Identifier
32493442
Citation
Trang-Poisson C, Kerdreux E, Poinas A, Planche L, Sokol H, Bemer P, Cabanas K, Hivernaud E, Biron L, Flet L, Montassier E, Le Garcasson G, Chiffoleau A, Jobert A, Lepelletier D, Caillon J, Le Pape P, Imbert BM, Bourreille A. Impact of fecal microbiota transplantation on chronic recurrent pouchitis in ulcerative colitis with ileo-anal anastomosis: study protocol for a prospective, multicenter, double-blind, randomized, controlled trial. Trials. 2020 Jun 3;21(1):455. doi: 10.1186/s13063-020-04330-1.
Results Reference
derived

Learn more about this trial

the Prophylaxis of Recurrent Pouchitis After Fecal Microbiota Transplant in UC With Ileo-anal Anastomosis

We'll reach out to this number within 24 hrs